|
注册号: Registration number: |
ChiCTR2000033388 |
|
最近更新日期: Date of Last Refreshed on: |
2020-05-31 11:01:14 |
|
注册时间: Date of Registration: |
2020-05-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国城市学龄儿童注意缺陷多动障碍(ADHD)调研 |
|
Public title: |
A nation-wide survey of ADHD in primary schools of urban areas in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国城市学龄儿童注意缺陷多动障碍(ADHD)调研 |
|
Scientific title: |
A nation-wide survey of ADHD in primary schools of urban areas in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李晓莉 |
研究负责人: |
柯晓燕 |
|
Applicant: |
Xiaoli Li |
Study leader: |
Xiaoyan Ke |
|
申请注册联系人电话: Applicant telephone: |
+86 15850767789 |
研究负责人电话:
Study leader's |
+86 13305176562 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lixiaoli821004@126.com |
研究负责人电子邮件: Study leader's E-mail: |
Kexynj@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区广州路264号 |
研究负责人通讯地址: |
江苏省南京市鼓楼区广州路264号 |
|
Applicant address: |
264 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
Study leader's address: |
264 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京脑科医院 |
||
|
Applicant's institution: |
Nanjing Brain Hospital |
||
|
研究负责人所在单位: |
南京脑科医院 |
||
|
Affiliation of the Leader: |
Nanjing Brain Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020-KY064-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京脑科医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Nanjing Brain Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-03-17 00:00:00 | ||
|
伦理委员会联系人: |
时影 |
||
|
Contact Name of the ethic committee: |
Ying Shi |
||
|
伦理委员会联系地址: |
江苏省南京市鼓楼区广州路264号 |
||
|
Contact Address of the ethic committee: |
264 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25-82296083 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京脑科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Brain Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市鼓楼区广州路264号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
264 Guangzhou Road, Gulou District, Nanjing, Jiangsu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
由西安杨森制药有限公司出资,资助公司仅提供资金支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
Funded by Xi'an Janssen Pharmaceutical Co., LTD., which only provides financial support |
||||||||||||||||||||||
|
研究疾病: |
注意缺陷多动障碍 |
||||||||||||||||||||||
|
Target disease: |
Attention deficit hyperactivity disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
通过调研全国七大地理区域选择符合要求的城市小学中所有符合要求的家长及教师,了解中国城市学龄儿童注意缺陷多动障碍(ADHD)的基本情况,同时探索通过医教结合模式改善ADHD诊疗的策略。 |
||||||||||||||||||||||
|
Objectives of Study: |
By investigating all the eligible parents and teachers in urban primary schools in seven major geographical regions of China, we can understand the basic situation of attention deficit hyperactivity disorder (ADHD)in Chinese urban school-age children, and explore the strategies to improve the diagnosis and treatment of ADHD through the combination of medical and education. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
家长排除标准: |
||||||||||||||||||||||
|
Exclusion criteria: |
Parent exclusion criteria: |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-09-01 00:00:00至 To 2022-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-09-01 00:00:00 至 To 2021-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
未使用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not used |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
预计将于2021年12月上传于发表学术刊物指定数据库,公众登陆刊物数据库自行查询 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upload the original data to database of the scientific publication publish our research paper in 2021.12, public can access the data in the database |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集为电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
An electronic data capture and management system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |